Dr. Krotee is an Investment Associate on the due diligence team at Kairos Ventures. She focuses on opportunities in the life sciences, spanning both therapeutics and medical devices across a range of indications such as oncology, retinal disease, and CNS disease. She spends most of her time sourcing opportunities from Kairos Ventures’ University Partners and completing due diligence on these opportunities. In addition, she serves on the Board of Directors of several Kairos Ventures portfolio companies: Linnaeus Therapeutics, Actuate Therapeutics, Siege, NVasc, and Holoclara. She also manages Kairos Ventures’ relationships with several of its University Partners.
She completed her PhD training in Molecular Biology at UCLA, where she studied the atomic structures of proteins associated with Alzheimer’s disease and type-II diabetes and she worked to create compounds that inhibited these structures. During that time, she also worked as a consultant for UCLA’s Business of Science Center. Prior to graduate school, Dr. Krotee was a Junior Specialist studying mosquito olfaction as a strategy for vector control at the Development Biology Center at UC Irvine. She holds a BS in Developmental and Cell Biology and Minor in Business Management from UC Irvine.